Could a triple therapy beat back tough liver cancer?
NCT ID NCT06881433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The goal was to see if the triple combination extends survival and shrinks tumors more than the standard two-drug approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hepatic arterial infusion chemotherapy (HAIC) added to immune checkpoint inhibitors and anti-VEGF drugs
What this could lead to
If successful, adding HAIC could improve survival and tumor shrinkage for people with advanced liver cancer that has spread into the portal vein.
What could go wrong
This is a completed study, but results are not yet published. Adding HAIC may increase side effects without clear benefit, and the findings may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongda Hospital
Nanjing, Jiangsu, China